<DOC>
	<DOCNO>NCT02247518</DOCNO>
	<brief_summary>The purpose study investigate effect tamsulosin pharmacokinetic property tadalafil</brief_summary>
	<brief_title>CKD-397 Drug-drug Interaction Study ( A )</brief_title>
	<detailed_description>This study randomize , open-label , mutiple dosing , 2-way crossover design evaluate pharmacokinetic effect tamsulosin ( 0.2mg ) tadalafil ( 5mg ) healthy male subject . Subjects receive repeat dose tadalafil ( 5mg*1t/day ) tadalafil ( 5mg*1t/day ) / tamsulosin ( 0.2mg*1t/day ) 5days . Each treatment period separate washout period least 10 day . Each period study enroll 8 healthy male subject . Blood sample pharmacokinetic analysis take regular interval dose . Safety assess measurement blood pressure , heart rate , safety laboratory data , review adverse event .</detailed_description>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Healthy man age 19 year less 55 year old time screening . BMI 17.5kg / m2 le 30.5kg / m2 weight 55kg Subject without congenital chronic disease psychotic symptom finding medical examination . Suitable subject determine laboratory test hematology test , blood chemistry , urinalysis test accord characteristic drug screen test ECG test . Subject fully understand clinical trial indepth explanation give prior clinical study , decide join clinical trial sign consent form approve Chonbuk National University Hospital IRB . Subjects able comply schedule visit , laboratory test procedure . Subject history blood , kidney , endocrine , respiratory , gastrointestinal , urinary , cardiovascular , hepatic , psychiatric , neurological allergic disease clinically significant ( Except untreated asymptomatic seasonal allergy time administration ) Subject history gastrointestinal disease gastrointestinal surgery affect drug absorption . Showing value correspond follow laboratory parameter : AST AST &gt; 2* upper limit normal range . Alcohol &gt; 210g/week , within 6 month prior screen . Taking medication involve clinical trial within two month first dose medication character . Sitting Systolic Blood Pressure ≥ 140 mmHg , Diastolic Blood Pressure ≥ 90 mmHg time screen . History alcohol drug abuse , within 1 year Positive result urine drug test ( Amphetamines , Cocaine , Opioid , Benzodiazepines , Cannabinoid ) Positive result Serology test ( Hepatitis B , Hepatitis C , HIV ( Human Immunodeficiency Virus ) , TPPA ( qual ) ) . Subject take abnormal meal affect ADME drug . Subjects treat metabolize enzyme inducer inhibitor barbital within 30days prior first dosing . Smoker ( &gt; 20cigarettes/day ) Subjects take ETC OTC medicine within 10days first IP administration . Subject do whole blood donation within two month component blood donation within 1 month prior first dose . Subject increase risk due clinical test administration drug Severe grade / chronic medical , mental condition abnormal laboratory result may interfere analysis test result . Subject take form organic nitrate periodically and/or intermittently . Subject know hereditary degenerative retinal disease include retinitis pigmentosa . Subject serious history hypersensitivity allergy investigational product . Subject Lost sight one eye Nonarteritic anterior ischemic optic neuropathy ( NAION ) . Subject genetic problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption . Orthostatic hypotension Subjects able comply guideline describe protocol . Subjects determine investigator 's decision unsuitable clinical trial participation .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Male</keyword>
	<keyword>Volunteers</keyword>
</DOC>